Lv6
1610 积分 2023-01-06 加入
Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
10小时前
已完结
Cancer registration in China and its role in cancer prevention and control
16小时前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
6天前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
6天前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
6天前
已完结
Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial
22天前
已完结
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study
24天前
已完结
Prognostic Nomogram for Hepatitis B Virus–related Hepatocellular Carcinoma With Adjuvant Transarterial Chemoembolization After Radical Resection
29天前
已完结
Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial
1个月前
已完结
Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2个月前
已完结
皖公网安备34019202002308
